%0 Journal Article
%@ 2374-2437
%A Leone, Gianmarco
%A Orlando, Francesco
%A Dutey-Magni, Peter
%A Vainauskas, Osvaldas
%A Grist, Emily
%A Ciani, Yari
%A Lall, Sharanpreet
%A Thakali, Suparna
%A Wingate, Anna
%A Wetterskog, Daniel
%A Sachdeva, Ashwin
%A Sydes, Matthew R
%A McPhail, Neil
%A Sreenivasan, Thiagarajan
%A O'Sullivan, Joe M
%A Clarke, Noel W
%A Parmar, Mahesh KB
%A Brown, Louise C
%A James, Nicholas D
%A Demichelis, Francesca
%A Attard, Gerhardt
%A the STAMPEDE collaborators
%D 2025
%F discovery:10205615
%I American Medical Association
%J JAMA Oncology
%T Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer:  the STAMPEDE Phase 3 Randomized Clinical Trial
%U https://discovery.ucl.ac.uk/id/eprint/10205615/
%X We previously reported that abiraterone acetate and prednisolone (hereafter abiraterone) added at initiation of androgen deprivation therapy (ADT) improved survival of metastatic and very high-risk locally advanced prostate cancer and that combining with enzalutamide did not change efficacy.1 Using next-generation sequencing on plasma DNA, we previously showed that genomic alterations of the androgen receptor (AR) gene contribute to resistance to abiraterone or enzalutamide when initiated for metastatic castration-resistant prostate cancer after progression with ADT alone.2 It is unknown whether hormone intensification at start of ADT alters selection of AR alterations within the gene body and/or enhancer region.3
%Z This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.